|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM171776054 |
| 003 |
DE-627 |
| 005 |
20231223130408.0 |
| 007 |
tu |
| 008 |
231223s2007 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0573.xml
|
| 035 |
|
|
|a (DE-627)NLM171776054
|
| 035 |
|
|
|a (NLM)17662658
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yang, Seung Hee
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Role of NKT cells in allogeneic islet graft survival
|
| 264 |
|
1 |
|c 2007
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.10.2007
|
| 500 |
|
|
|a Date Revised 21.11.2008
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Although NKT cells expressing CD1d-reactive TCR exerted protective role in autoimmune diseases, the regulatory function of CD1d-dependent NKT cells in alloimmune responses has not been investigated thoroughly. Here, we demonstrated the regulatory effects of NKT cells using a pancreas islet transplantation model. CD40/CD154 blocking induced long-term graft survival in most B6 recipients, but B6.CD1d(-/-) recipients showed co-stimulation blockade-resistant rejection. Adoptive transfer of NKT cells into B6.CD1d(-/-) restored tolerizing capacity of co-stimulatory blockade. Activation of NKT cells was effective for the prolongation of graft survival and up-regulated membrane-bound TGF-beta expression transiently on their cell surface. The activated CD1d-dependent NKT cells inhibited alloantigen-driven cell proliferation through cell contacts and the beneficial effect of CD154 blocking for allograft survival was related to TGF-beta pathway. Thus, we can conclude that NKT cells are essential for the stable allograft survival and the regulatory function is dependent on, at least in part, TGF-beta engagement
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, CD1
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD1d
|2 NLM
|
| 650 |
|
7 |
|a Histocompatibility Antigens Class II
|2 NLM
|
| 650 |
|
7 |
|a Transforming Growth Factor beta
|2 NLM
|
| 700 |
1 |
|
|a Jin, Ji Zhe
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Se Han
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Hyungbae
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Chi Hwa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Dong-Sup
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Suhnggwon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chung, Nam Hyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Yon Su
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 124(2007), 3 vom: 01. Sept., Seite 258-66
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:124
|g year:2007
|g number:3
|g day:01
|g month:09
|g pages:258-66
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 124
|j 2007
|e 3
|b 01
|c 09
|h 258-66
|